Systemic Endotoxemia, Inflammatory Activation, and Lipid Dysregulation in Parkinson's Disease: Evidence from Circulating LPS-Related Biomarkers and Plasma Lipids.
Level 4 - case-series / case-control
Case-control observational study comparing patients to matched controls
PubMed 42123298 · doi:10.3390/ijms27093711
What was done
Researchers compared circulating lipopolysaccharide (LPS), LPS-handling proteins, inflammatory markers, and lipid profiles between 20 Parkinson's disease (PD) patients and 20 matched controls. Fasting venous blood samples were analyzed for LPS via Limulus amebocyte lysate (LAL) assay, and lipopolysaccharide binding protein (LBP), soluble CD14 (sCD14), high-sensitivity C-reactive protein (hsCRP), and phospholipid transfer protein (PLTP) via ELISAs. Standard biochemical assays measured serum total cholesterol, HDL-cholesterol (HDL-C), phospholipids, HDL-phospholipids, and triacylglycerols (TAGs).
What was found
The abstract does not report exact numerical values, effect sizes, or p-values. It reports that circulating LPS concentrations did not differ between PD patients and controls. However, PD patients had elevated sCD14, hsCRP, and PLTP, alongside reduced LBP levels. For lipids, PD patients had lower total cholesterol, lower HDL-C, and lower HDL-associated phospholipids compared to controls, with no significant difference in TAG levels. Inflammatory markers and lipid fractions demonstrated distinct correlation patterns between the two groups.
Why it matters
The findings suggest that altered innate immune handling of endotoxins and dysregulated lipid metabolism (specifically HDL fractions) may co-occur in Parkinson's disease pathology, even without a gross increase in total circulating LPS levels.
Limits
The sample size is very small (n=20 per group), limiting statistical power and generalizability. The cross-sectional case-control design precludes causal inference. The abstract does not provide exact numerical values, measures of variance, or details regarding participant demographics, disease severity, or medication use (e.g., dopaminergic therapies or statins) that could confound lipid and inflammatory measurements.
Cited by
- partial Elevated circulating levels of lipopolysaccharide (LPS) and anti-LPS antibodies correlate with Parkinson's disease, Alzheimer's disease, and multiple sclerosis.